MedTrace Logo

Buprenorphine and Naloxone Combination Study - 10

NCT00015288 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2017-01-12

No results posted yet for this study

Summary

The purpose of this study is to examine pharmacokinetics and dose proportionality of sublingual tablets containing varying doses of buprenorphine and naloxone.

Conditions

  • Heroin Dependence
  • Opioid-Related Disorders

Interventions

DRUG

Buprenorphine/naloxone

Sponsors & Collaborators

  • New York MDRU

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • John Rotrosen, M.D. · New York MDRU

Study Design

Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00015288 on ClinicalTrials.gov